Literature DB >> 9636552

Demographic considerations in tacrolimus pharmacokinetics.

W E Fitzsimmons1, I Bekersky, D Dressler, K Raye, E Hodosh, Q Mekki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636552     DOI： 10.1016/s0041-1345(98)00275-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  16 in total

1.  A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.

Authors:  Alan L Buchman; Mary F Paine; Anita Wallin; Shana S Ludington
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

2.  Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients.

Authors:  Anita Grover; Lynda A Frassetto; Leslie Z Benet; Harini A Chakkera
Journal:  Drug Metab Dispos       Date:  2011-08-17       Impact factor: 3.922

3.  Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy.

Authors:  M J García Sánchez; C Manzanares; D Santos-Buelga; A Blázquez; J Manzanares; P Urruzuno; E Medina
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 4.  Overview of extended release tacrolimus in solid organ transplantation.

Authors:  Neha Patel; Abigail Cook; Elizabeth Greenhalgh; Megan A Rech; Joshua Rusinak; Lynley Heinrich
Journal:  World J Transplant       Date:  2016-03-24

5.  Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin.

Authors:  T Zolfino; M A Heneghan; S Norris; P M Harrison; B C Portmann; I G McFarlane
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  The MDR1 (ABCB1) gene polymorphism and its clinical implications.

Authors:  Ichiro Ieiri; Hiroshi Takane; Kenji Otsubo
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants.

Authors:  Wen-Yuan Johnson Kuan; Nathalie Châteauvert; Vincent Leclerc; Benoît Drolet
Journal:  Can J Hosp Pharm       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.